$5.55 EPS Expected for Biogen Inc. (BIIB) This Quarter
Equities research analysts predict that Biogen Inc. (NASDAQ:BIIB) will post $5.55 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Twenty Nine analysts have issued estimates for Biogen’s earnings, with the highest EPS estimate coming in at $6.07 and the lowest estimate coming in at $4.80. Biogen reported earnings per share of $5.04 in the same quarter last year, which indicates a positive year over year growth rate of 10.1%. The company is expected to issue its next earnings report on Thursday, January 25th.
On average, analysts expect that Biogen will report full-year earnings of $22.07 per share for the current financial year, with EPS estimates ranging from $21.35 to $22.61. For the next financial year, analysts anticipate that the firm will post earnings of $23.82 per share, with EPS estimates ranging from $20.87 to $25.83. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Biogen.
Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating the Zacks’ consensus estimate of $5.70 by $0.61. The firm had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The firm’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.19 EPS.
A number of brokerages have weighed in on BIIB. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $350.00 target price on shares of Biogen in a report on Wednesday. Vetr raised shares of Biogen from a “buy” rating to a “strong-buy” rating and set a $319.53 target price on the stock in a report on Thursday, August 10th. Mizuho set a $400.00 target price on shares of Biogen and gave the stock a “buy” rating in a report on Monday, November 13th. Goldman Sachs Group Inc raised shares of Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 target price on the stock in a report on Wednesday, August 16th. Finally, BidaskClub raised shares of Biogen from a “hold” rating to a “buy” rating in a report on Friday, August 4th. Twelve research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Biogen currently has an average rating of “Buy” and a consensus target price of $341.89.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Prentiss Smith & Co. Inc. boosted its position in shares of Biogen by 14.9% during the 2nd quarter. Prentiss Smith & Co. Inc. now owns 385 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 50 shares in the last quarter. Atlantic Trust LLC bought a new position in shares of Biogen during the 2nd quarter valued at about $114,000. Independent Portfolio Consultants Inc. boosted its position in shares of Biogen by 93.2% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 454 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 219 shares in the last quarter. Horan Capital Advisors LLC. bought a new position in shares of Biogen during the 3rd quarter valued at about $128,000. Finally, Massey Quick Simon & CO. LLC boosted its position in shares of Biogen by 84.8% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 195 shares in the last quarter. Hedge funds and other institutional investors own 88.28% of the company’s stock.
Shares of Biogen (NASDAQ BIIB) traded down $0.83 during trading hours on Wednesday, hitting $308.97. 514,110 shares of the company’s stock were exchanged, compared to its average volume of 1,053,036. The firm has a market capitalization of $65,515.54, a PE ratio of 14.35, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. Biogen has a 52 week low of $244.28 and a 52 week high of $348.84. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.